and difficult in coordination movements. No evidence of peripheral lymphadenopathy or hepatosplenomegaly was noted on physical examination.
INTRODUCTION
Hodgkin Lymphoma (HL) is a unique hematopoietic neoplasm characterized by the presence of neoplastic Reed-Sternberg (RS) cells in an inflammatory background. Central nervous system (CNS) involvement in systemic HL is fairly uncommon, with incidence as low as 0.02% of all HL cases, most of which are due to relapsing systemic involvement or progressive disease. [1] Primary CNS-HL is even more rare with only 22 cases have been reported in the literature and summarized by Cecyn et al. [2] In this report, we present a primary CNS-HL in an immunocompetent patient without evidence of disease recurrence after 7 years of follow-up.
CASE REPORT
A 38-year-old Caucasian gentleman with no prior significant history presented with headache, vomiting, and frequent falls over the course of 2 months. Physical examination revealed normal vital signs. Neurological assessment showed left-sided ataxia, dysmetria, muscular hypotonia, In light of previous findings, the patient was deemed a candidate for surgical resection of tumor and underwent complete tumor resection.
Histopathological examination of the mass using hematoxylin and eosin-stained sections showed mixed cell background with multiple scattered RS cells. The RS cells were immunoreactive for CD30 marker and were negative for CD20 and ALK-1 markers. CD3 and CD5 markers highlight the small background lymphocytes [ Figure 2 ]. The overall findings were most compatible with classical HL, mixed cellularity type.
Bone marrow biopsy was also obtained for staging and was found to be normal. Lumbar puncture revealed clear cerebrospinal fluid (CSF) with normal protein, glucose, and white blood cell count. No malignant cells were seen on microscopic examination of centrifuged CSF sample. HIV test was negative.
Postoperative course was uneventful. The patient received whole-brain radiation with a dose of 4000 centigray (cGy) followed by a boost of 1000 cGy, which was targeted toward the resection site. Chemotherapy containing two courses of adriamycin, bleomycin, vinblastine, and dacarbazine was given to prevent tumor recurrence and metastasis.
The patient was followed regularly with routine physical and neurological examination, laboratory tests (complete blood count, erythrocyte sedimentation rate, and lactate dehydrogenase), MRI of the brain, and low-dose CT scan of the neck, chest, abdomen, and pelvis at 3, 6, 12, 24, and 36 months postoperatively [ Figure 3 ]. No evidence of recurrence was noted over the course of 7 years.
DISCUSSION
CNS has been commonly thought of as an immune-isolated organ without any connection with the peripheral immune system. However, recent discoveries showed that the brain has an active lymphatic network presents in the meninges, with heavy immunocytes (lymphocytes, monocytes, macrophages, and dendritic cells) shift from these lymph vessels to the CNS tissue through the blood-brain barrier. This movement helps the peripheral immune system perform active surveillance inside the CNS, even in normal physiologic conditions. [3] While the CNS is rich in lymphocytes, the incidence of HL in CNS remains exceedingly rare with only 22 cases reported in the literature and summarized by Cecyn et al., [2] which raises the questions about the role of predisposing in the development of primary CNS-HL. In the CNS, immunocytes reside under a rigid control from CNS Tregs, specifically CD25+ T-cells which are capable of restricting proliferation and cytokines production from these immunocytes. Impaired function of the CNS Tregs leads to negative consequences. For example, if this function is decreased, this may activate autoreactive T-and B-lymphocytes in the CNS leading to an autoimmune reaction similar to that in multiple sclerosis, or increased neurodegeneration due to excessive immune response similar to what's observed in Parkinson's disease. [3, 4] Other studies suggested that overactivation of Tregs or increase their numbers may weaken the immune response and antitumor immunity and might favor tumor development or growth. [3, 5] In addition, recent studies showed that the number and activity of Tregs (especially CD4+ CD25+) in the HL tissues are very high, and it would be expected to exert profound local immunosuppressive effects by inhibiting both interleukin-2 (IL-2) production and the upregulation of IL-2 Ra-chain (CD25) expression, thus delaying or blocking the activation of CD8+ and natural killer cells to tumor antigens, which leads to protection of RS cells from immunological surveillance and clearance. [6] [7] [8] [9] The presence of Tregs in the microenvironment around RS may have a prognostic value. Furthermore, some reports suggested that the increased numbers of Tregs might have a positive prognostic value in cHL, [10] while others found the prognostic value to be dependent on the ratio of Tregs to other background infiltrating cells rather than its absolute numbers. [11] The high ratio of Tregs in the microenvironment around RS cells over T-helper 2 is associated with significantly shortened disease-free survival, while a low ratio improved disease-free survival, which supports the suggestion of the inhibitory effects on antitumor immune response mediated by Tregs. [12] The paucity of primary CNS-HL cases makes it more difficult to identify the risk factors associated with the development of this malignancy. Family history of HL and male gender have been considered risk factors. [13] The role of immunosuppression and Epstein-Barr virus infection in systemic and primary CNS-HL have also been suggested. [14] The presence of EBV in RS cells correlates with increased Tregs (CD4+CD25+FOXP3+) quantification in the tumor microenvironment and decreases the antitumor immunity toward RS. Fortunately, the presence of EBV with HL does not impact the survival in these patients. [15] Better understanding of the role of Tregs in HL pathogenesis will help in development of more efficient therapies with less toxicity than the traditional radiation and chemotherapy, especially in cases of CNS-HL. For example, adoptive transfer of cytotoxic lymphocytes may be more effective if combined with measures to overcome this regulatory cell activity. [8] 
CONCLUSION
We report an exceedingly rare case of primary CNS-HL in an immunocompetent patient, with no evidence of systemic involvement found after the staging process. In this report, we also discuss the role of Tregs in the CNS immune system. While little is known about etiology, optimal management, and the prognosis of such case, we discuss the role of impaired function of Tregs in the CNS in the development and progression primary CNS HLs. Further insight into the pathophysiology will help establish unique and less toxic treatment for such cases compared to traditional therapy used in HLs.
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